EMEmma Macdonald‐Laurs

Emma Macdonald‐Laurs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emma Macdonald‐Laurs has a total of 163 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Sound Environment in the PICU : A Scoping Review Describing Sound Levels, Interventions and Patient Impacts

    by Janeen Bower, Hazel Low, Naomi Khan, Sebastian J. Corlette, Emma Macdonald‐Laurs, Andrea Veysey, Ben Gelbart, Kate Masterson

    Elevated sound levels are associated with increased morbidity in adult and neonatal intensive care; however, their impact in the paediatric intensive care unit (PICU) remains poorly characterised. The aim of this scoping review was to characterise sound exposure in the PICU, including its measurement, sources, and associations with patient outcomes. MEDLINE, Embase, PsycINFO (Ovid), and PubMed were searched up to 5 November 2025 for full‐text, peer‐reviewed publications within the past 10 years to reflect the contemporary PICU environment. Titles, abstracts, and full texts were independently screened by two authors, and results were reported according to the PRISMA Extension for Scoping Reviews. Thirty‐six publications were included. Publications were grouped into five domains: measurement of sound levels; sources of sound; patient impacts; sound reduction interventions including care bundles incorporating sound descriptions; and other. Reported sound levels varied substantially across studies, reflecting heterogeneity in measurement approaches and clinical contexts. Most studies reported sound levels above WHO recommendations, and several reported maximum levels exceeding 80 dBA. Sound sources were broadly categorised as medical equipment, human activity, and environmental factors. Links between elevated sound and clinically meaningful outcomes remain uncertain. Intervention studies were limited, often behaviour‐focused, and rarely evaluated patient‐centred outcomes or clinical sustainability. Current evidence suggests WHO recommended sound levels are rarely achieved. The sound environment in the PICU is multifaceted, reflecting the interaction of clinical equipment, human activity, and environmental systems. There is a need for interventional research to evaluate whether modification of the PICU sound environment meaningfully improves patient outcomes.

  • Open Access

    Attitudes toward sodium valproate use, withdrawal, and counseling in people of reproductive potential: A scoping review

    by Katherine Wang, Sarah Loveday, Monica S. Cooper, Emma Macdonald‐Laurs

    Regulatory restrictions and evolving clinical guidelines have aimed to reduce sodium valproate use in people of reproductive potential over the past decade due to its teratogenic risk. While clinical evidence and policy responses are well established, stakeholder perspectives remain less explored. This scoping review synthesizes the existing evidence on the attitudes of patients, caregivers and healthcare professionals regarding sodium valproate use, withdrawal and counseling in females of childbearing age. This scoping review, conducted according to JBI Methodology for a Scoping Review and registered on Open Science Framework ( https://doi.org/10.17605/OSF.IO/HK7QN ), analyzed studies which directly reported on, or measured, the attitudes of patients, caregivers and/or healthcare professionals regarding the use of sodium valproate for epilepsy in females. A structured search across four databases (EMBASE, Web of Science, MEDLINE, PsycINFO) and the gray literature was performed. A thematic synthesis of data was conducted to identify important themes and concepts. A total of 22 studies including 14 peer‐reviewed articles and 8 gray literature sources met the inclusion criteria, including only 2 qualitative studies. Most literature focused on patient and caregiver perspectives ( n = 15), with fewer addressing healthcare professional views ( n = 7). Methodology incorporating interviews ( n = 2) or free‐text survey responses ( n = 3) was uncommon. Across the studies, three key themes emerged: (i) patient disempowerment due to limited knowledge and suboptimal counseling and risk communication; (ii) the influence of maternal identity formation on attitudes, behaviors and decision‐making when navigating sodium valproate use; and (iii) concerns regarding regulatory responses, such as pregnancy prevention programs, particularly around implementation challenges, perceived paternalism and lack of individualized care. Published evidence on stakeholder attitudes toward sodium valproate use in people of reproductive potential remains limited. The existing literature highlights gaps in awareness, counseling, and patient‐centered delivery of pregnancy prevention programs. Future research should prioritize qualitative studies to better understand stakeholder attitudes and experiences to inform future guidelines and clinical practice. Plain Language Summary: Sodium valproate is an antiseizure medication that can harm an unborn baby when used during pregnancy. National and international programs have been introduced to reduce its use among people who could become pregnant. This review explored the perspectives of patients, caregivers and healthcare providers regarding sodium valproate use and withdrawal. Key themes included experiences of disempowerment relating to risk communication, the influence of maternal identity on treatment decisions and concerns about regulatory approaches. These findings highlight factors contributing to challenges with pregnancy prevention programs, in particular gaps in shared decision‐making, communication and patient‐centered care.

  • Open Access

    Late-onset epileptic spasms: presentation, aetiology and outcome

    by Sameer Dal, Emma Macdonald-Laurs, Simone Mandelstam, Rachel Kerr, Eunice K Chan, Kathryn Santamaria, Wirginia Maixner, Alison Wray, Colleen D’ARcy, Ramja Kokulan, et al.

    Late-onset epileptic spasms (LOES) are epileptic spasms (ES) commencing after age 12 months, often misdiagnosed and having uncertain relationship to infantile spasms. Previous studies of mostly small LOES cohorts frequently reported ‘cryptogenic’ aetiologies. We studied the presentations, aetiologies, treatment responses and outcomes in a large LOES cohort, evaluated with modern neuroimaging and genomic testing. In this retrospective cohort study, 62 children with video-confirmed epileptic spasms, diagnosed between 2011 and 2021, were included. All had epileptiform activity on EEG, but none had hypsarrhythmia. Median age at epileptic spasms onset was 23 months (range 1–15 years) and median delay to diagnosis was 8 months (interquartile range: 3–15). Only 24% children were correctly diagnosed at presentation, common misdiagnoses being myoclonic epilepsies and non-epileptic phenomenon. Aetiology was identified in 95%. Structural-malformative aetiologies were present in 63% (most commonly focal cortical dysplasia and mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy). Other aetiologies were structural-acquired in 13% (mostly postnatal stroke and CNS infections), genetic in 13% (mostly intragenic variants and chromosomopathies) and oncological in 6% (history of leukaemia, two with CNS involvement). Children with structural aetiologies often had normal development prior to onset of epileptic spasms, a later median age of epileptic spasms onset and were more likely to have asymmetric or subtle epileptic spasms and additional seizures prior to epileptic spasms. Epileptic spasms ceased in 29% children treated with prednisolone, most having genetic aetiologies and in 35% treated with vigabatrin, all having structural-malformative aetiologies. Apart from clobazam, which was effective in 17% of children, all other antiseizure medications, vagus nerve stimulation and ketogenic diet therapy were ineffective. Epileptic spasms ceased in 86% (18/21) of children who underwent epilepsy surgery. At median follow-up of 10.3 years, 53% children were free of all seizures and 76% were free of epileptic spasms. More children with unilateral structural-malformative aetiologies achieved seizure freedom than other aetiologies, most commonly following surgery but occasionally following treatment with vigabatrin or clobazam. Impairment of cognitive function or adaptive behaviour (formally assessed in 90%) was significantly more common in children with genetic than structural aetiologies, and in children with ongoing seizures than seizure freedom. Among children who underwent epilepsy surgery, 62% achieved average or low-average adaptive functioning or normal intellectual capacity. This study highlights the importance of prompt recognition of epileptic spasms in older children for improved seizure and developmental outcomes. Brain malformations and insults are the predominant causes of LOES, and when unilateral, respond best to epilepsy surgery.

  • Open Access

    Language fMRI lateralization success and head motion in pediatric epilepsy patients with ADHD, and improvements based on fMRI task training

    by Bonnie Alexander, Kathryn Santamaria, Sila Genc, Sarah Barton, Michael Kean, Alison Wray, Wirginia Maixner, Emma MacDonald-Laurs, Joseph Ym Y.-M. Yang

    Introduction: Language functional MRI (fMRI) is a valuable tool for presurgical planning in epilepsy. Functional MRI can be challenging in children, and head motion can compromise its utility. The candidacy of patients with ADHD for fMRI is sometimes queried regarding concerns about possible head motion. In 2020, we implemented an fMRI task training program, via telehealth and/or mock MRI. We aimed to determine whether training increased language lateralisation success and/or reduced head motion in all patients, and in those with ADHD. We also aimed to determine whether patients with ADHD exhibited more head motion during fMRI than those without ADHD. Methods: We retrospectively identified 223 epilepsy (85%) and other neurosurgery patients, (241 scans including repeats) with language fMRI at Royal Children’s Hospital, Melbourne, Australia, 2016-2024. There were 24 individuals with ADHD listed in the Electronic Medical Record, five of whom had diagnoses of both ADHD and autism; and nine with autism. Language lateralisation success was determined by clinician description recorded as left/right/bilateral in the medical record. 99 patients were provided the training including fMRI task practise. Head motion was quantified by maximum Framewise Displacement (FD max ; mm). Results: ADHD was associated with lower language lateralisation success. Training was associated with greater language lateralisation success, across all patients, and in those with ADHD. Regarding ADHD and head motion, outliers in FD max were seen in 5 young patients with ADHD. Data were trimmed to allow separate investigation of FD max for the sample with and without extremes of head motion. In untrimmed data, FD max was significantly higher in patients with ADHD than in those without. In trimmed data, FD max was on average lower in patients with ADHD than those without, however this was not statistically supported. Regarding training and head motion, across all patients, FD max was significantly lower for scans with training than without. In patients with ADHD, FD max was on average lower for scans with training, however training was not associated with FD max . Conclusions: Language fMRI training was associated with higher language lateralization success, particularly in patients with ADHD. Training was associated with reduced head motion across all patients. Although some young patients with ADHD had substantial head motion, most in our sample did not move more than those without ADHD. We conclude that the training program increases success of language fMRI, and that an ADHD diagnosis should not be a contraindication to language fMRI.

  • Open Access

    KCNQ2 neonatal epilepsy: Impact of prompt diagnosis and treatment, and early predictors of outcome severity

    by Trupti Jadhav, Sophie E. Bouffler, Emily Innes, Michael Fahey, Matthew Hunter, Kavitha Kothur, Sebastian Lunke, Matthew Lynch, Emma Macdonald‐Laurs, Elizabeth Emma Palmer, et al.

    Objective: To determine whether prompt genetic diagnosis in children with KCNQ2 neonatal epilepsy enabling targeted therapy is associated with improved outcomes, and identify early predictors of developmental outcomes. Methods: Thirty‐seven children with KCNQ2 neonatal epilepsy were recruited from five pediatric centers. We reviewed demographic, clinical, EEG, and genetic data. We determined differences in outcomes between individuals with prompt (greater than 30 days from seizure onset) and later genetic diagnosis, and we identified neonatal factors associated with developmental outcome. Results: Baseline characteristics were similar between children with prompt ( n = 6, median age at genetic diagnosis 15 days) and later ( n = 31, median age 309 days, p < .05) diagnosis. All with prompt diagnosis received sodium channel blocking (SCB) anti‐seizure medication (ASM) in the neonatal period compared with 15/31 (48%) in the later diagnosis group. Children with prompt diagnosis had higher rates of seizure freedom at age 12 months than those with later diagnosis (6/6 [100%] vs. 17/31 [54%]; p .049], and lower number of emergency department representations (median 0 vs. 2), and hospital readmissions (median 0 vs. 1). Factors in the neonatal period associated with abnormal developmental outcome included neurological abnormalities (e.g., abnormal tone) and markedly abnormal neonatal EEG background (11/11 [100%] with markedly abnormal EEG vs. 11/24 [46%] with normal to moderately abnormal EEG). Significance: Prompt genetic diagnosis was associated with targeted therapy, resulting in improved seizure control and reduced hospital representation. Clinical features present in the neonate assist in predicting outcome severity, which is critically important in counselling families receiving a KCNQ2 diagnosis soon after seizure onset. Plain Language Summary: In KCNQ2 neonatal epilepsy, sodium channel blocking antiseizure medicines are recommended, but the benefits of starting treatment early have been uncertain. Our findings show that prompt genetic diagnosis enabled early targeted treatment, with potential to improve outcomes. Specifically, prompt genetic diagnosis was associated with improved seizure control and reduced hospital visits compared with delayed diagnosis. However, a prospective, long‐term study is needed to determine whether early treatment also improves developmental outcomes. Predicting outcome severity in newborns remains challenging, although abnormal neurological examination and markedly abnormal EEG in the newborn period were linked to abnormal developmental outcomes.


  • Open Access

    Lingual Dyskinesia as the Presenting Feature of Acquired Demyelinating Syndrome: A Case Report and Review of Differential Diagnoses

    by Briana Davis, Ahmed Kaki, Eppie M. Yiu, Emma Macdonald‐Laurs

    Learning Points: Acquired demyelinating syndromes may present with movement disorders, including lingual dyskinesia. The differential diagnosis for abnormal tongue movements includes: acquired demyelinating syndromes, structural lesions involving the basal ganglia, brainstem or cerebral cortex, stroke, tics, adverse drug reactions, systemic autoimmune conditions including Sydenham's chorea, and genetic conditions. In the absence of an alternative explanation, MRI brain should be undertaken in children presenting with new onset abnormal tongue movements.

  • Open Access

    Metabolic Stroke: Atypical Presentation of Succinic Semialdehyde Dehydrogenase Deficiency

    by Sharmila Kiss, Richard J. Leventer, Cormac Duff, Emma Macdonald‐Laurs, Olivia‐Paris Quinn, Fahaz Nazer, Michelle Cao, Abisha Srikumar, Jenzen Dalina, Mary Eggington, et al.

    Succinic semialdehyde dehydrogenase (SSADH) deficiency is a rare autosomal recessive neurometabolic disorder caused by biallelic pathogenic variants in ALDH5A1 , encoding the mitochondrial enzyme SSADH. This enzyme catalyses the conversion of succinic semialdehyde to succinic acid in the γ‐aminobutyric acid (GABA) degradation pathway. SSADH deficiency leads to the accumulation of neurotoxic metabolites, including γ‐hydroxybutyrate (GHB), and presents with developmental delay, hypotonia, ataxia, seizures, behavioral disturbances, and intellectual disability. We report a 10‐month‐old Caucasian male with global developmental delay, central hypotonia, and delayed motor milestones. He presented acutely with left‐sided hemiplegia following irritability and vomiting. Brain MRI showed bilateral (right > left) T2 hyperintensities and diffusion restriction in the globus pallidus. Urine organic acid analysis via gas chromatography–mass spectrometry revealed markedly elevated 4‐hydroxybutyric acid and 4,5‐dihydroxyhexanoic lactone, pathognomonic for SSADH deficiency. Molecular testing identified compound heterozygous ALDH5A1 variants: c.278G>T p.(Cys93Phe) and c.612G>A p.(Trp204*), both previously reported as pathogenic. Parental segregation confirmed trans configuration. Three weeks postillness, he developed focal seizures, which have remained well controlled on levetiracetam. His seizure onset in infancy is notably earlier than the typical early childhood onset (~9 years) reported in SSADH deficiency. This case expands the phenotypic spectrum of SSADH deficiency to include metabolic stroke as a presenting feature in infancy and highlights the importance of early recognition and molecular confirmation to guide management and emerging therapeutic strategies.

  • Valproate Prescribing for Female Adolescents and Management of the Associated Teratogenicity Risk, Royal Children's Hospital, Melbourne, 2022–2024: A Retrospective Audit of Medical Records Data

    by Briana Davis, Monica S. Cooper, Michael South, Jeremy L. Freeman, Emma Macdonald‐Laurs

    Objectives: To assess the frequency of valproate prescribing for female patients of childbearing age at the Royal Children's Hospital, Melbourne, and to assess the frequency of documented discussions with these patients about the teratogenicity of valproate and the discussions or prescribing of contraception. Study Design: Retrospective audit of hospital electronic medical records data; analysis of Pharmaceutical Benefits Scheme (PBS) valproate dispensing data. Setting, Participants: 13‐ to 18‐year‐old girls or women prescribed valproate at the Royal Children's Hospital, Melbourne during 29 May 2022–29 May 2024; PBS valproate dispensing data for Australia for the 2023 calendar year. Main Outcome Measures: Characteristics of adolescent female patients prescribed valproate; documented discussions of valproate‐related teratogenicity, and discussions or prescribing of contraception; population valproate prescribing rates for Australia and by state. Results: Valproate was prescribed for 245 female patients aged 13–18 years during 2022–2024 (median age, 16 years; interquartile range [IQR], 14–17 years); the median prescribed daily dose was 600 mg (IQR, 400–800 mg; range, 200–2000 mg). Valproate was prescribed for treating epilepsy for 221 patients (90%), including 97 (44%) with drug‐resistant epilepsy; 160 patients (65%) had neurodevelopmental disabilities. Teratogenicity was discussed with 32 patients (13%), less frequently with patients with a neurodevelopmental disability (9% vs. 20%; odds ratio [OR], 0.41; 95% confidence interval [95% CI], 0.19–0.88). Contraception was discussed with 69 patients (28%); the proportion was larger for patients with neurodevelopmental disabilities (34% vs. 16%; OR, 2.66; 95% CI, 1.37–5.14). Contraception was prescribed for 50 patients (20%); the proportion was larger for patients with neurodevelopmental disabilities (25% vs. 12%; OR, 2.50; 95% CI, 1.18–5.30). The national PBS‐subsidised dispensing rate during 2023 was 621 per 100,000 girls and women aged 13–18 years; in Victoria it was 556 per 100,000 girls and women aged 13–18 years. Conclusion: Despite the risk of teratogenicity, valproate was prescribed for a considerable number of female adolescents at the Royal Children's Hospital during 2022–2024 and across Australia during 2023. Its teratogenicity was discussed with few patients, nor were discussions or prescribing contraception frequent. Contraception was more frequently discussed and prescribed for patients with neurodevelopmental disability, but teratogenicity was discussed less often.


  • Bilateral frontal periventricular nodular heterotopia: a distinctive cortical malformation

    by Ine Hoogwijs, Simone A. Mandelstam, George McGillivray, Benjamin J. Halliday, Eppie M. Yiu, Emma Macdonald-Laurs, David Perry, Rakesh Patel, Michael Gabbett, Chirag Patel, et al.


  • Open Access

    Cerebral Cavernous Malformations Presenting With Epileptic Spasms in Children

    by Jia Yi Tonkin, Lauren Taylor, Emma Macdonald-Laurs